Pancreas Clinical Trials

1 recruiting

Pancreas Trials at a Glance

150 actively recruiting trials for pancreas are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 2 with 38 trials, with the heaviest enrollment activity in New York, Boston, and Philadelphia. Lead sponsors running pancreas studies include Minia University, Chongqing Precision Biotech Co., Ltd, and IRCCS San Raffaele.

Treatments under study

About Pancreas Clinical Trials

Looking for clinical trials for Pancreas? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pancreas trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pancreas clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 150 trials

Recruiting
Phase 1Phase 2

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Locally Advanced Pancreatic AdenocarcinomaLocally Advanced Pancreas CancerLocally Advanced Pancreatic Ductal Adenocarcinoma
Xerient Pharma36 enrolled4 locationsNCT07157033
Recruiting
Phase 3

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

Carcinoid TumorCarcinoid Tumor of PancreasCarcinoid Tumor of Liver+6 more
Crinetics Pharmaceuticals Inc.141 enrolled51 locationsNCT07087054
Recruiting
Phase 2

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Pancreas Cancer
Shandong Cancer Hospital and Institute25 enrolled1 locationNCT06050317
Recruiting
Phase 1

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Pancreatic CancerMetastatic Pancreatic Ductal AdenocarcinomaCancer of the Pancreas
Washington University School of Medicine51 enrolled1 locationNCT06648434
Recruiting
Not Applicable

Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening

Pancreatic Ductal AdenocarcinomaPancreas CancerHereditary Diseases+1 more
Lipidica, a.s.419 enrolled16 locationsNCT06549725
Recruiting

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

CholangiocarcinomaPancreas CancerColorectal Neoplasms+2 more
National Cancer Institute (NCI)1,800 enrolled1 locationNCT01915225
Recruiting

Pancreatic Cancer Early Detection Consortium

Pancreatic Ductal AdenocarcinomaPancreas CancerGenetic Predisposition+1 more
Arbor Research Collaborative for Health20,000 enrolled60 locationsNCT04970056
Recruiting

Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma

Pancreas Cancer
Institut Bergonié50 enrolled1 locationNCT06705335
Recruiting
Phase 1Phase 2

Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

Adenocarcinoma of the Pancreas
West Virginia University40 enrolled1 locationNCT04911816
Recruiting
Phase 3

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

Pancreas CancerOligometastatic
M.D. Anderson Cancer Center80 enrolled1 locationNCT06593431
Recruiting
Phase 2

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Pancreatic CancerPancreas CancerPancreatic Adenocarcinoma+1 more
Washington University School of Medicine36 enrolled1 locationNCT07126158
Recruiting
Not Applicable

Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma

Adenocarcinoma of the Pancreas
The University of Texas Health Science Center at San Antonio40 enrolled1 locationNCT07340151
Recruiting
Phase 2

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

Adenocarcinoma of the Pancreas
National Cancer Institute, Naples240 enrolled5 locationsNCT05821556
Recruiting
Not Applicable

Patients With Pancreatic Tumor: Use of an App to Monitor Progress in a Simple and Intuitive Way by Periodically Completing Targeted Questionnaires and Providing Educational and Informational Content.

Pain ManagementCaregiverPancreatectomy+3 more
Casa di Cura Dott. Pederzoli185 enrolled2 locationsNCT07532590
Recruiting
Phase 2

Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

Neuroendocrine Carcinomas (NEC)Neuroendocrine Carcinoma of PancreasNeuroendocrine Carcinoma of Prostate
Inkeun Park60 enrolled4 locationsNCT06893783
Recruiting
Phase 1

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Breast CancerOvarian CancerProstate Cancer+6 more
Nammi Therapeutics Inc100 enrolled10 locationsNCT06582017
Recruiting
Phase 2Phase 3

CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients

Kidney Pancreas Transplantation
University of Wisconsin, Madison20 enrolled1 locationNCT03769298
Recruiting

Collection of Circulating Biomarkers in Pancreatic Cancer

Pancreas Cancer
Abramson Cancer Center at Penn Medicine30 enrolled1 locationNCT05743049
Recruiting
Phase 1

Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma

Adenocarcinoma Pancreas
Northwell Health10 enrolled1 locationNCT07253662
Recruiting
Phase 2

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Pancreas AdenocarcinomaLocally Advanced Pancreatic AdenocarcinomaBorderline Resectable Pancreatic Adenocarcinoma
Wake Forest University Health Sciences64 enrolled1 locationNCT05825066